[email protected]
  1. Home
  2. Pharmaceuticals
  3. 040-000-296 Ritonavir, CAS 155213-67-5

040-000-296 Ritonavir, CAS 155213-67-5

ritonavir
SKU: 040-000-296 Category:
Get A Quote






  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Synonym Norvir
Type Antibiotics, protease, tyrosine kinase inhibitor
Keywords COVID-19, HIV, antiviral, AIDS, SARS-CoV-2
Related products Piperaquine, Chloroquine Diphosphate, Artemisinin, Acrichin Dihydrochloride
Description

Description

Ritonavir Specifications

Product Name Ritonavir
CAS Registry Number 155213-67-5
Molecular Formula C37H48N6O5S2
Molecular Weight 720.946 g/mol
Purity 98%
Appearance White powder
Package 1kg-25kg
Shelf life 2 years
Functions Antiviral, therapy for HIV-1, potential inhibitor of COVID-19

Ritonavir Description

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. The mechanism of action of the anti-HIV drug lopinavir and ritonavir is to block the enzymes required for virus replication. Lopinavir/ritonavir have been shown to reduce coronavirus levels that cause SARS and MERS in animal studies.

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.

ritonavir

ritonavir

Ritonavir Applications

Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older).

Reference:

  1. L. Morissette; S. Soukasene; D. Levinson; M. J. Cima; O. Almarsson (2003). “Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization”
  2. Hsieh, Yi-Ling; Ilevbare, Grace A.; Van Eerdenbrugh, Bernard; Box, Karl J.; Sanchez-Felix, Manuel Vincente; Taylor, Lynne S. (2012-05-12). “pH-Induced Precipitation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid State Properties”. Pharmaceutical Research. 29 (10): 2738–2753.
  3. Nieminen, Tuija H.; Hagelberg, Nora M.; Saari, Teijo I.; Neuvonen, Mikko; Neuvonen, Pertti J.; Laine, Kari; Olkkola, Klaus T. (2010). “Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir”. European Journal of Clinical Pharmacology. 66 (10): 977–985.
Related Products